Abstract
BackgroundPatients on standard dialysis, in particular those on high-flux and high-efficiency dialysis, are exposed to hundreds of liters of dialysis-water per week. The quality of dialysis-water is a factor responsible for inflammation in dialysis patients. Inflammation is a potent trigger of atherosclerosis and a pathogenetic factor in anemia, increasing mortality and morbidity in dialysis patients. Current systems for water treatment do not completely eliminate bacteria and endotoxins. This prospective study tested whether improved dialysis-water purity by an additional ultrafilter can reduce inflammation and ameliorate hemoglobin levels, with a consequent reduction in erythropoietin-stimulating agents (ESA).MethodsAn ultrafilter, composed of two serially positioned devices with polysulfone membranes of 2.0 and 1.0 m2, respectively, was positioned within the fluid pathway before the dialysis machine. Prevalent dialysis patients were assigned either to continue dialysis with conventional dialysis-water (control phase) or to initiate dialysis sessions with improved dialysis-water purity (study phase). After 6 months, patients were crossed over. Total study duration was 1 year. Routine chemistry, bacterial count, endotoxin levels in dialysis-water as well as blood levels of pro- and anti-inflammatory cytokines, human serum amyloid A, C-reactive protein and fraction 5 of complement were measured.ResultsThirty-two patients completed the study. Mean bacterial count was lower and endotoxin levels were absent in dialysis-water obtained with the ultrafilter. At the end of the study-phase, C-reactive protein and pro-inflammatory cytokines decreased while anti-inflammatory ones increased. Hemoglobin levels were improved with lower ESA doses.ConclusionsAn additional ultrafilter improved dialysis-water purity, reduced levels of inflammation markers, ameliorated hemoglobin concentration with reduced ESA doses. These results remain speculative but they may generate studies to assess whether improved dialysis-water quality with an ultrafilter can reduce inflammation and improve survival of dialysis patients.
Highlights
Inflammation plays a critical role in mortality and morbidity of dialysis patients, being a potent trigger of atherosclerosis and a pathogenetic factor in anemia [1,2,3,4,5]
This study aimed to test in patients on dialysis whether an additional ultrafilter can decrease blood levels of markers of inflammation, increase hemoglobin levels (Hb) and reduce doses of erythropoietin-stimulating agents (ESA)
The present study evaluated the efficacy of an additional ultrafilter in reducing blood levels of several indicators of inflammation, ameliorating Hb concentration and reducing the level of ESA doses required
Summary
Inflammation plays a critical role in mortality and morbidity of dialysis patients, being a potent trigger of atherosclerosis and a pathogenetic factor in anemia [1,2,3,4,5]. There are several factors linked to uremia that can cause inflammation; some can be regarded as modifiable risk factors This is the case of quality of dialysis-water. Current systems for water treatment do not completely remove bacteria and endotoxins [6,7,8]. Patients on conventional dialysis, in particular those on high-flux and high-efficiency dialysis, are exposed to hundreds of liters of dialysis-water per week. Current systems for water treatment do not completely eliminate bacteria and endotoxins. This prospective study tested whether improved dialysis-water purity by an additional ultrafilter can reduce inflammation and ameliorate hemoglobin levels, with a consequent reduction in erythropoietin-stimulating agents (ESA). Prevalent dialysis patients were assigned either to continue dialysis with conventional dialysis-water (control phase) or to initiate dialysis sessions
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have